abstract: OBJECTIVE: To evaluate @entity1212 survival and identify mechanisms involved in @entity1212 @entity3885 during a 109.8 @entity1 -year experience with implanted pumps for peritoneal @entity2690 delivery. RESEARCH DESIGN AND METHODS: Fifty-one type I @entity6 @entity1 were recruited in feasibility studies of two models of implanted systems for peritoneal @entity2690 delivery. Both systems had a @entity1346 -coated @entity691 @entity1212 and infused Hoechst 21 PH neutral @entity2690 (U400 or U100). Catheter obstruction was suspected each time the increase of @entity2690 flow rate over 50% of usual need was insufficient to correct an impairment of glycemic control in the absence of of intercurrent factors. A laparoscopic examination was then systematically performed under general anesthesia. The disclosed material occluding the @entity1212 was submitted to a pathological analysis. By actuarial analysis, we examined the estimated effects of the potential determinants of the catheters' duration of proper operation on @entity1212 survival. RESULTS: Over an implantation duration of 25.8 +/- 14.0 months (mean +/- SD), 34 @entity1212 @entity3885 were diagnosed in 24 @entity1 , resulting in an incidence of 31 events per 100 @entity1 -years. Fifty percent survival rate of the first implanted @entity1212 was 27 months (95% confidence interval [CI]: 19-32) on actuarial analysis. Six catheters were cleared under laparoscopy and 24 were replaced, while 2 systems were definitively explanted and 2 combined replacements of pump and @entity1212 were performed because of an associated pump slowdown. In five cases, an alkaline rinse procedure of the pump was necessary after @entity1212 replacement to restore usual @entity2690 needs, suggesting an associated @entity2690 aggregation in the pump. Twenty @entity3885 were due to a fibrin clot at the @entity1212 tip, and 14 @entity3885 were created by a tissue encapsulation around the @entity1212 . A previous experience of peritoneal @entity2690 infusion from portable pumps or a longer duration of @entity6 ( > 21 years) both appeared as conditions significantly reducing the time of a @entity1212 's proper operation (P < 0.01 and P < 0.05, respectively) either by @entity3885 or by encapsulations. Pathological analysis of @entity1212 encapsulations showed a collagen fibrosis in all studied @entity1 (n = 11), which was associated with a lymphocytic infiltrate in five @entity1 and also with anti- @entity2690 immunoreactive @entity527 in four @entity1 . Catheter tip clots were composed of fibrinlike material, nonreactive to anti- @entity2690 antibodies. CONCLUSIONS: Catheter obstruction is a frequent adverse technical event occurring with implanted @entity2690 pumps. Progress is expected in the biocompatibility of @entity1212 material and more specifically in the stability of @entity2690 preparations to prevent immuno-inflammatory reactions and @entity2690 @entity527 that appear to be involved in @entity1212 failures.

title: Catheter complications associated with implantable systems for peritoneal XXXX delivery. An analysis of frequency, predisposing factors, and obstructing materials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity691 :: ('MESH:D020959', 'Chemical') :: ['polyethylene']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['amyloid deposits']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructions', 'tip obstructions']

entities_list: @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone']

answer: @entity2690 :: (3630,Gene) :: ['insulin']


abstract: Studies among long-term survivors of childhood @entity5 who had received high-dose irradiation therapy of 4-60   Gy, demonstrated acute and chronic dental effects, including @entity2520 . However, the possible effects of low to moderate doses of radiation on dental health are sparse. The aim of this study is to investigate the association between childhood exposure to low-moderate doses of ionizing radiation and periodontal health following 50   years since exposure. The study population included 253 irradiated subjects (treated for @entity3100 in the 1950s) and, 162 non-irradiated subjects. The estimated dose to the teeth was 0.2-0.4   Gy. Dental examination was performed according to the community periodontal index (CPI). Socioeconomic and health behavior variables were obtained through a personal questionnaire. @entity2520 was operationally defined as "deep periodontal pockets." A multivariate logistic regression model was used for the association of irradiation status and other independent variables with periodontal status. The results showed that among the irradiated subjects, 23%, (95% CI 18-28%) demonstrated complete edentulousness or insufficient teeth for CPI scoring as compared to 13% (95% CI 8-19%) among the non-irradiated subjects (p   =   0.01). @entity2520 was detected among 54% of the irradiated subjects as compared to 40% of the non-irradiated (p   =   0.008). Controlling for education and smoking, the ORs for the association between radiation and periodontal disease were 1.61 (95% CI 1.01-2.57) and 1.95 (95% CI 1.1-3.5) for ever never and per 1   Gy absorbed in the salivary gland, respectively. In line with other studies, a protective effect for @entity2520 among those with high education and an increased risk for ever smokers were observed. In conclusion, childhood exposure to low-moderate doses of ionizing radiation might be associated with later outcomes of dental health. The results add valuable data on the long-term health effects of exposure to ionizing radiation and support the implementation of the ALARA principle in childhood exposure to diagnostic procedure involving radiation.

title: Long-Term Effects of Exposure to Ionizing Irradiation on Periodontal Health Status - The XXXX Cohort Study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity3100 :: ('MESH:D014006', 'Disease') :: ['Tinea capitis']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['Periodontal disease', 'periodontal diseases']

answer: @entity3100 :: (MESH:D014006,Disease) :: ['Tinea capitis']


abstract: The occurrence of spontaneous @entity272 in Japanese newts (Cynops pyrrhogaster) from Niigata prefecture in Northern Japan was monitored over four seasons covering a period of 2 years. Of 13,613 newts, 249 were found to @entity1185 . The percentage of newts with @entity1185 was highest in autumn, ranging from 1.93 to 5.45% of the total average. These values were more than four times as high as values obtained in the other three seasons (0.16 to 0.50%). A total of 12,167 newts were collected from their natural environment in 10 prefectures of Japan in the autumn of 1980 and 1981. Newts collected from the northern, seaside prefectures had @entity1185 rates (1.00 to 5.45%) than did newts from the Southern, Pacific Ocean prefectures of Japan (0 to 0.27%). Male and female newts were affected equally often by the @entity189 . @entity778 -like bodies, resembling @entity778 , were found in the cytoplasm of the @entity189 . These @entity778 -like bodies were not seen in the control epithelium of newts with normal skin and without @entity1185 or in nonaffected regions of newts with @entity1185 . It is suggested that @entity5 and @entity778 are causally related.

title: Seasonal and geographical changes of spontaneous XXXX in the Japanese newt Cynops pyrrhogaster.

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['herpes-type virus', 'Virus', 'virus']

entities_list: @entity1185 :: ('MESH:D010212', 'Disease') :: ['papillomas', 'possess papillomas', 'higher papilloma', 'papilloma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['epitheliomas']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin papillomas']

answer: @entity272 :: (MESH:D012871,Disease) :: ['skin papillomas']


abstract: During the autumn and winter of 2004 and 2005, an extensive outbreak of waterborne @entity7014 occurred in Bergen, Norway. Over 1,500 @entity1 were diagnosed with @entity7014 . Analysis of water from the implicated source revealed low numbers of @entity45 , but the initial contamination event probably occurred up to 10 weeks previously. While sewage leakage from a residential area is now considered to be the probable source of contamination, during the episode waste from one particular septic tank was thought to be a possible source. Genotyping of cysts from the septic tank demonstrated that they were assemblage A cysts, although the sequences were not identical to any previously published sequences. For the beta-giardin gene, the closest published subgenotype was subgenotype A3; for the @entity29521 gene, the closest published subgenotype was subgenotype A2. Genotyping of cysts from 21 @entity1 samples revealed that they were assemblage B cysts; thus, the septic tank was unlikely to be the contamination source. Sequencing of the beta-giardin and @entity29521 genes from @entity1 samples and a comparison of the sequences gave complex results. For the beta-giardin gene, three isolates had sequences identical to subgenotype B3 sequences. However, other isolates had between one and four single-nucleotide polymorphisms (SNPs). For the @entity29521 gene, none of the sequences were identical to the sequence published for subgenotype B3, and the sequences had between one and three SNPs. One isolate, which was identical to subgenotype B3 at the beta-giardin gene, was more similar to subgenotype B2 at the @entity29521 gene. Grouping the isolates on the basis of SNPs resulted in different groups for the two genes. The results are discussed in relation to @entity7014 in Norway and to other Giardia genotyping studies.

title: Application of genotyping during an extensive outbreak of waterborne XXXX in Bergen, Norway, during autumn and winter 2004.

entities_list: @entity45 :: ('MESH:D010181', 'Disease') :: ['Giardia cysts']

entities_list: @entity7014 :: ('MESH:D005873', 'Disease') :: ['giardiasis']

answer: @entity7014 :: (MESH:D005873,Disease) :: ['giardiasis']


abstract: PURPOSE: The purpose of this study was to develop evidence-based guidelines on @entity282 management via the web and to examine the effects in terms of @entity158 level of @entity1 undergoing abdominal surgery and nurses' knowledge of @entity282 management. METHODS: First, evidence-based @entity158 guidelines were developed via the web in a tertiary hospital. Second, a special educational program on evidence-based @entity158 guidelines for nurses was developed after validation of content by experts. Third, diverse strategies were adopted in order to facilitate incorporation of evidence-based @entity158 guidelines in practice. Fourth, nurses in the study units were educated on evidence-based guidelines using the developed educational program for 3 weeks before their implementation of evidence-based @entity158 guidelines to @entity1 . @entity1 were assigned to the control group (from July 29 to August 20, 2011) and the experimental group (from September 24 to October 25, 2011) according to interrupted time interval. The data were analyzed using chi-square test, analysis of variance test with Scheff  's test as a post hoc and repeated measure of analysis of variance. RESULTS: @entity1 in the experimental group showed a significantly lower level of @entity158 . Nurses' knowledge of management of @entity282 showed a significant increase after installation of evidence-based guidelines. CONCLUSION: Evidence-based @entity158 guidelines were effective in reducing the @entity158 level of @entity1 as well as improving nurses' knowledge of @entity158 management.

title: Effect of evidence-based XXXX guidelines via web for @entity1 undergoing abdominal surgery in South Korea.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity282 :: (MESH:D010149,Disease) :: ['postoperative pain']


abstract: The effects of chronic (2 weeks) @entity3190 on the production of very low density lipoprotein (VLDL) @entity412 and on VLDL particle size were examined. @entity3190 was induced by a constant sc infusion of 6 U porcine insulin/day from an osmotic minipump. To avoid profound @entity4053 , these @entity35 received chow plus 10% @entity969 in their drinking water. Therefore, two control groups were examined; one receiving chow plus the same amount of @entity969 (high @entity1735 control) and the other receiving chow only (chow control). The constant infusion model was compared to a previously reported model of @entity3190 . In that model, NPH insulin was injected for 2 weeks twice daily in incrementally increasing doses (final dose, 6 U/day) into @entity35 that were also fed chow and given 10% @entity969 drinking water. Results with the injection model were similar to those previously reported: an increase in @entity412 production in face of a decrease in FFA, a minimal decrease in serum @entity412 , and some decrease in serum @entity413 . The infusion model produced the same increase in @entity412 production and decrease in @entity844 concentration. However, it differed in producing an increase in serum @entity412 and no change in serum @entity413 . The former suggested that in the infusion model @entity412 removal was not stimulated as much as in the injection model. Since there was no @entity4053 in the infusion model, it was unlikely that VLDL changes were caused by an increase in counter regulatory hormones. VLDL particle size was increased in the high @entity1735 controls. This indicated that changes in @entity969 supplementation led to the production of more @entity412 -filled VLDL particles. @entity3190 was not accompanied by any further increase in particle size. Thus, the @entity3190 -induced increase in VLDL- @entity412 production was accompanied by an equivalent increase in VLDL particle production.

title: Changes in very low density lipoprotein particle size and production in response to XXXX feeding and @entity3190 .

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity3190 :: ('MESH:D006946', 'Disease') :: ['Hyperinsulinemia', 'hyperinsulinemia']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity969 :: (MESH:D013395,Chemical) :: ['sucrose']


abstract: OBJECTIVE: To evaluate the efficacy of r @entity901 plus @entity1487 /leucovorin @entity460 (LV) combined with concurrent radiotherapy in the treatment of local advanced @entity356 . METHODS: 83 @entity1 with local advanced @entity356 were randomized into 2 groups. Group I (n = 40) underwent irradiation at the dose of 40 - 45 Gy 5 times a week on the @entity5 and the lymph nodes with the size > or = 10 mm in @entity851 , and receiving intravenous drip of @entity15114 85 mg/m2 for 2 h, intravenous injection of LV 200 mg/m2, and then intravenous injection of 5-fu 300 mg/m2, followed by continuous intravenous infusion of 5-fu 500 mg/m2, for 22 h, with 2 weeks as a cycle. Three cycles of chemotherapy were given during the radiotherapy. Then operative evaluation was conducted. Those resectable underwent operation and then 3 cycles of adjuvant chemotherapy. Those un-resectable underwent continuous 3 cycles of chemotherapy. Group II (n = 43) received only chemotherapy. The treatment was repeated until disease progression or prohibitive @entity137 . RESULTS: 38 @entity1 were evaluated in Group I, the result showed complete remission (CR) in 4 @entity1 (10.5%), partial remission (PR) in 23(60.5%), no-change (NC) in 7(18.4%), @entity74 ( @entity74 ) in 5(13.2%), with the remission rate (RR) of 71% (27/40). 42 @entity1 were evaluated in Group II, the result showed CR in 3 @entity1 (7.14%), PR in 16(14.3%), NC in 13(30.9%), and @entity74 in 9(26.2%)with the RR of 45% (19/43). The resection rates of Groups I and II were 32.5% and 27.9% respectively (P = 0.649). The R0 resection rates of Groups I and II were 77.8% and 57.1% respectively (P = 0.161). The mean survival times of the resectable @entity1 in Groups I and II were 45 months and 28 months respectively, and the 2-year overall survival (OS) of the resectable @entity1 in Groups I and II were 65.8% and 56.3% respectively (P = 0.371). The mean survival times of the un-resectable @entity1 in Groups I and II were 14 months and 9 months respectively, and the 2-year OS rates of the un-resectable @entity1 in Groups I and II were 28.3% and 20.7% respectively (P = 0.017). The toxic and adverse effects included @entity1503 . There was no treatment-related @entity204 . CONCLUSION: Radiotherapy combined with concurrent chemotherapy may be an effective and well-tolerated regimen in @entity1 with advanced and metastatic @entity356 .

title: [Efficacy of @entity901 plus @entity1487 /leucovorin @entity460 combined with concurrent radiotherapy for local advanced XXXX ].

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['short axis']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['gastrointestinal and hematological toxicity']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: BACKGROUND: @entity1 with @entity308 tend to process negative information with regard to the self (i.e. self-referential processing). A better understanding of the neural underpinnings of self-referential processing in @entity1 with @entity308 is clinically important as it can inform on potential treatment targets. METHOD: This fMRI study sought to study the neural correlates of self-referential processing in @entity1 with chronic @entity308 (cMDD) (n=17) and non- @entity1 controls (n=18) using a passive processing paradigm. Stimuli consisted of positive, negative, negative @entity308 related and @entity1314 trait words or non-words. @entity1 were instructed to indicate whether a presented word was an existing word or a non-word while undergoing an fMRI scan. @entity1 also completed an explicit and an implicit measure of positive and negative self-associations outside the scanner. RESULTS: Non- @entity1 controls had relatively increased activity in the medial prefrontal cortex (mPFC) during processing of negative @entity308 related vs. neutral words whereas @entity1 with cMDD had relatively decreased activity. Non- @entity1 controls had relatively increased dorsolateral prefrontal cortex (dlPFC) activity during processing of positive vs. neutral words whereas @entity1 with cMDD had relatively decreased activity. Explicit but not implicit self-associations with @entity308 related words were associated with neural activity in the mPFC and the dlPFC. LIMITATIONS: The study did not include a clinical control group and therefore the specificity of findings remains unknown. CONCLUSIONS: The distinct neural processing of emotional self-relevant stimuli in the mPFC and the dlPFC in @entity1 with cMDD might represent an emotional blunting response towards negative self-relevant stimuli.

title: Neural correlates of self-referential processing and implicit self-associations in chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Participants']

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['neutral personality']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'major depressive disorder']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with @entity0 ( @entity0 ): @entity3003 ( @entity3003 ) - gemcitabine ( XXXX ) combination is effective and well tolerate.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

answer: @entity8178 :: (CHEBI:74858,Chemical) :: ['GCB']


abstract: The aim of the investigation was to determine the patterns of cerebral involvement on computed tomography (CT) and magnetic resonance (MR) imaging in @entity6079 . Four @entity1 between the ages of 2 and 11 years presented over a 5-year period with a diagnosis of @entity6079 . Their imaging studies and clinical data were reviewed retrospectively. The medical histories of all four @entity1 were noncontributory except for recent bouts of chickenpox 1 week to 3 months prior to hospitalization. Three @entity1 presented with @entity191 manifestations. Bilateral, symmetric hypodense, nonenhancing @entity21 were found on CT. These areas showed nonenhancing low signal intensity on T1-weighted images and high signal intensity on T2-weighted images on MR. One @entity1 presented with diffuse, multiple gray and @entity62 of similar imaging characteristics; some lesions, however, did enhance. This @entity1 had no gait disturbances. @entity6079 can produce two patterns of dramatic CT and MR findings. With an appropriate history and clinical findings, varicella as a cause of bilateral basal ganglia or diffuse @entity75 can be differentiated from other possible etiologies which include @entity130 , @entity519 , @entity209 and @entity17 .

title: MR and CT imaging patterns in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'child']

entities_list: @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelinating diseases']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cerebral lesions']

entities_list: @entity6079 :: ('MESH:D020804', 'Disease') :: ['Post-varicella encephalitis', 'post-varicella encephalitis']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['parkinsonian']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disorders']

entities_list: @entity21 :: ('MESH:D001480', 'Disease') :: ['basal ganglia lesions']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['white matter lesions']

answer: @entity6079 :: (MESH:D020804,Disease) :: ['post-varicella encephalitis']


abstract: Renal blood flow falls in both kidneys following delivery of a clinical dose of shockwaves (SW) (2000 SW, 24 kV, Dornier HM3) to only one kidney. The role of @entity8 in this response was examined in a porcine model of renal denervation. Six-week-old @entity1707 underwent unilateral renal denervation. Nerves along the renal artery of one kidney were identified, sectioned and painted with 10% @entity3971 . Two weeks later the @entity1707 were anesthetized and baseline renal function was determined using inulin and PAH clearances. Animals then had either sham-shockwave lithotripsy (SWL) (group 1), SWL to the innervated kidney (group 2) or SWL to the denervated kidney (group 3). Bilateral renal function was again measured 1 and 4 h after SWL. Both kidneys were then removed for analysis of @entity1063 content to validate the denervation. Renal plasma (RPF) flow was significantly reduced in shocked innervated kidneys (group 2) and shocked denervated kidneys (group 3). RPF was not reduced in the unshocked denervated kidneys of group 2. These observations suggest that @entity8 play a pivotal role in modulating the vascular response of the contralateral unshocked kidney to SWL, but only a partial role, if any, in modulating that response in the shocked kidney.

title: XXXX mediate changes in contralateral renal blood flow after extracorporeal shockwave lithotripsy.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal nerves']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Renal nerves']


abstract: BACKGROUND: Occupational exposure to solvents may lead to @entity2359 and @entity25 . We aimed to investigate the association of occupational exposure to petroleum-derived @entity9436 with @entity2359 and @entity25 . METHODS: We included male workers handling/distributing petroleum products (exposed, n   =   250) and electricians (non-exposed, n   =   250) from two companies in Tlemcen (Algeria). @entity2359 was evaluated with the Q-16 questionnaire, and @entity25 with the Epworth and the Berlin questionnaires. Multivariable Poisson regression models with @entity2246 were applied obtaining risk ratios (RR) and their 95% confidence interval (CI). RESULTS: Overall, the prevalence of reported @entity2359 and @entity25 was higher in exposed than in non-exposed workers. Significant adjusted associations were observed for @entity2359 , snoring, and @entity25 (RR   =   2.2, CI: 1.7-2.8; RR   =   1.4; CI: 1.1-1.7; RR   =   1.3, CI: 1.2-1.5, respectively). No significant associations were observed with the Epworth score. CONCLUSIONS: Our questionnaire-based cross-sectional study suggests that exposure to petroleum-derived @entity9436 is associated with self-reported @entity25 and @entity2359 symptoms. Am. J. Ind. Med. 59:129-136, 2015.    2015 Wiley Periodicals, Inc.

title: Sleep disturbances and XXXX in workers exposed to @entity9436 . An observational study from Algeria.

entities_list: @entity2246 :: ('MESH:D008661', 'Disease') :: ['robust error variances']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance symptoms', 'excessive sleepiness', 'sleep disturbances']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity', 'Neurotoxicity']

entities_list: @entity9436 :: ('MESH:D006838', 'Chemical') :: ['hydrocarbons']

answer: @entity2359 :: (MESH:D020258,Disease) :: ['neurotoxicity']


abstract: From 1979 through 1986, 90 @entity1 required intraaortic balloon pumping (IABP) due to @entity998 complicating open heart surgery. Preoperatively, functional class III or IV was present in 92%; in @entity1 with @entity453 (n = 54), three-vessel or left main disease was found in 72%; @entity1 with @entity340 (n = 37) generally had multiple surgical procedures or valve re-replacement performed. Intra-IABP mortality was 49% (n = 44) and 30-day mortality 61% (n = 55). The latter figure decreased from 75% in 1979-81 to 53% in 1985-86. Cumulative 5-year survival was 22%. Logistic regression analysis identified as independent predictors of 30 day mortality the necessity for adjuvant treatment with the more powerful "pressure drugs" @entity3044 / @entity1063 , number of @entity4289 , functional classes III-IV, and chronic @entity1002 . Different combinations of these risk factors identified different @entity1 groups with 30-day mortalities ranging from 100% to 0%. The risk factors reflected both @entity712 probably due to severe @entity63 and @entity454 due to advanced @entity66 . Taking the high-risk composition of the material into account, a 5-year survival of 22% cannot be regarded as discouraging. Continued employment of IABP treatment in open heart surgery, using an aggressive approach coupled with individualized inotropic support, seems justified.

title: Intraaortic balloon pumping in the treatment of XXXX following open heart surgery--immediate results and long-term prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4289 :: ('MESH:D054221', 'Disease') :: ['DC-defibrillations']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['acute cardiac failure']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease']

entities_list: @entity998 :: ('MESH:D002303', 'Disease') :: ['low cardiac output']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['isoprenaline']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular disease']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular failure']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['chronic failure']

answer: @entity998 :: (MESH:D002303,Disease) :: ['low cardiac output']


abstract: BACKGROUND AND PURPOSE: @entity731 occurs later and is less extensive in intracranial arteries than in extracranial arteries. However, the mechanisms responsible are poorly understood. A previous study has suggested a better antioxidant protection of intracranial arteries. METHODS: To assess the influence of age on arterial activity of antioxidant enzymes and atherogenesis, we compared intracranial and extracranial arteries of @entity1 of different ages who retrospectively lacked confounding classic risk factors (48 premature fetuses aged 6.4+/-0.8 months [mean+/-SD], 58 @entity1 aged 7.9+/-3.8 years, 42 adults aged 42.5+/-5.1 years, and 40 elderly subjects aged 71.8+/-3.4 years; all males). Lesions were quantified by computer-assisted imaging analysis of sections of the middle cerebral and basilar arteries, the left anterior descending coronary artery, the common carotid artery, and the abdominal aorta. Macrophages, @entity755 , oxidized LDL, and @entity1495 in lesions were determined by immunocytochemistry. The effect of aging on atherogenesis was then compared with that on the activity of 4 antioxidant enzymes in the arterial wall. RESULTS: @entity731 was 6- to 19-fold greater (P<0.01) in extracranial arteries than in intracranial arteries, and it increased linearly with age. Intracranial arteries showed significantly greater antioxidant enzyme activities than did extracranial arteries. However, the antioxidant protection of intracranial arteries decreased significantly in older age, coinciding with a marked acceleration of atherogenesis. An increase in @entity1495 protein expression and in gelatinolytic activity consistent with the degree of @entity4522 was also observed. CONCLUSIONS: These results suggest that a greater activity of antioxidant enzymes in intracranial arteries may contribute to their greater resistance to atherogenesis and that with increasing age intracranial arteries respond with accelerated atherogenesis when their antioxidant protection decreases relatively more than that of extracranial arteries.

title: Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in @entity1 without classic risk factors for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'humans']

entities_list: @entity755 :: ('338', 'Gene') :: ['apolipoprotein B']

entities_list: @entity1495 :: ('4318', 'Gene') :: ['matrix metalloproteinase-9']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['Atherosclerosis']

entities_list: @entity4522 :: ('MESH:D002537', 'Disease') :: ['intracranial atherosclerosis']

answer: @entity731 :: (MESH:D050197,Disease) :: ['atherosclerosis']


abstract: A series of 18 @entity89 is reviewed. The ages of the 11 males and 7 females ranged from 11 to 65 years with a mean age of 37.4 years. The maxilla was involved in 10 cases whereas the mandible was the site of disease in 8 @entity1 . A widened periodontal space was an invariably present radiological feature in those @entity1 in whom the @entity5 involved the tooth-bearing area of the jaw. Treatment consisted of radical surgery with incidental radiotherapy or chemotherapy as adjuvant therapy. The local recurrence rate was 36% whereas the rate of @entity3 was 40%. A five year survival time free of disease was shown by 47%. Prognosis was found to be adversely influenced by a high age and a high grade of @entity5 as determined by counting mitoses. Features that distinguish @entity89 from @entity5 elsewhere in the skeleton are a higher mean age of occurrence, a lower rate of @entity3 , a longer period of time before clinical manifestation of @entity3 and a more favourable prognosis. Factors that could be responsible for this variation in behaviour are discussed.

title: XXXX . Analysis of 18 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity89 :: ('MESH:D007571', 'Disease') :: ['jaw osteosarcomas', 'jaw osteosarcoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['histological malignancy', 'tumours', 'tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity89 :: (MESH:D007571,Disease) :: ['Osteosarcoma of the jaw bones']


abstract: BACKGROUND: Oral @entity1544 (OCSCC) accounts for 2% to 3% of all @entity5 and has a high mortality rate. The majority of anticancer drugs are of natural origin. However, it is unknown whether the medicinal plant Thymus vulgaris L. (thyme) is cytotoxic towards @entity213 ( @entity213 ). MATERIALS AND METHODS: @entity137 of thyme essential oil was investigated on the @entity213 cell line, UMSCC1. The IC       of thyme essential oil extract was 369  g/ml. Moreover, we performed pharmacogenomics analyses. RESULTS: Genes involved in the cell cycle, cell death and @entity5 were involved in the cytotoxic activity of thyme essential oil at the transcriptional level. The three most significantly regulated pathways by thyme essential oil were interferon signaling, N-glycan biosynthesis and @entity6976 ( @entity6976 ) signaling. CONCLUSION: Thyme essential oil inhibits @entity1 @entity213 cell growth. Based on pharmacogenomic approaches, novel insights into the molecular mode of anticancer activity of thyme are presented.

title: @entity137 of Thymus vulgaris essential oil towards XXXX @entity1544 .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Cytotoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancies']

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['cavity squamous cell carcinoma']

entities_list: @entity6976 :: ('5598', 'Gene') :: ['ERK5', 'extracellular signal-regulated kinase 5']

entities_list: @entity213 :: ('MESH:C535575', 'Disease') :: ['head and neck squamous cell carcinoma', 'HNSCC']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity1 with mesial @entity1315 (mTLE) frequently show @entity73 . However, the relation between mTLE and @entity73 is poorly understood. To gain more insight into @entity302 -associated alterations in cognitive performance, we studied the spatial learning of C57BL/6J @entity19 five weeks after @entity4176 -induced @entity159 ( @entity159 ). Typically, structural hippocampal rearrangements take place within five weeks after @entity159 . @entity19 were monitored by exposing them to four tasks with a focus on spatial memory and @entity148 : the circular hole board, modified hole board, novel object-placement task, and elevated plus maze. On the circular hole board, animals showed a higher preference for hippocampus-independent strategies after @entity159 . In contrast, no change in strategy was seen on the modified hole board, but animals with @entity159 were able to finish the task more often. Animals did not have an increased preference for a relocated object in the novel object-placement task but showed an increased locomotion after @entity159 . No indications for altered @entity148 were found when tested on the elevated plus maze following @entity159 . These data suggest that the circular hole board is a well-suited paradigm to detect subtle @entity159 -induced @entity131 .

title: @entity4176 -induced epileptogenesis alters circular hole board learning strategy but not the performance of C57BL/6J XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['hippocampal deficits']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'cognitive deficits']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['temporal lobe epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus', 'SE']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: @entity369 decarboxylase (ADC) is a key enzyme involved in the synthesis of @entity4663 , which have been implicated in a wide range of plant responses, including stress. However, regulation of @entity4664 levels in relation to ADC in response to stress at the molecular level is not well understood. In an attempt to address this question, we first cloned two cDNAs in mustard ( @entity13344 _ Coss var. @entity13344 ), designated MADC2 and MADC3, encoding predicted ADC. MADC2 and MADC3 encode polypeptides of 692 and 680 @entity535 residues, respectively. A comparison of deduced @entity535 sequence revealed that both were highly homologous to MADC1 (77%), a mustard ADC, and other plant ADCs (63-84%). Northern analysis revealed that ADC transcripts in mustard were generally more abundant in stem and root but were barely detectable in leaf. However, ADC expression in the leaf was up-regulated differentially in response to stress such as chilling, salt and @entity2656 and to treatments with exogenous @entity4663 . While chilling induced expression of all three ADC genes, salt predominantly resulted in increased accumulation of MADC3 transcript. Leaves exhibited a similar response to exogenous @entity7224 , @entity11667 and @entity8037 , all of which stimulated accumulation of MADC2 and MADC3 transcripts but not MADC1. Furthermore, exogenous @entity7224 also increased the endogenous levels of @entity11667 and @entity8037 , while a higher endogenous @entity7224 and @entity11667 content was detected in leaf incubated with exogenous @entity8037 . Leaves also responded to chilling, salt and @entity2656 by increasing the levels of the cellular @entity4664 content, in which the level of @entity8037 in free and conjugated forms increased most profoundly.

title: Up-regulation of XXXX decarboxylase gene expression and accumulation of @entity4663 in mustard ( @entity13344 )in response to stress.

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity8037 :: ('MESH:D013096', 'Chemical') :: ['spermine']

entities_list: @entity7224 :: ('MESH:D011700', 'Chemical') :: ['putrescine']

entities_list: @entity4663 :: ('MESH:D011073', 'Chemical') :: ['polyamines']

entities_list: @entity4664 :: ('CHEBI:60143', 'Chemical') :: ['polyamine']

entities_list: @entity13344 :: ('3707', 'Species') :: ['Indian Mustard', 'Brassica juncea[L.] Czern']

entities_list: @entity369 :: ('CHEBI:29016', 'Chemical') :: ['Arginine']

entities_list: @entity11667 :: ('MESH:D013095', 'Chemical') :: ['spermidine']

answer: @entity369 :: (CHEBI:29016,Chemical) :: ['arginine']


abstract: PURPOSE: A complete set of subtelomeric fluorescent DNA probes, except the acrocentric p-arms, was developed in 1996, was optimized in 1998, and is commercially available. These and other fluorescence in situ hybridization (FISH) probes have been used to detect anomalies of the subtelomere regions among groups of @entity1 with @entity1032 (MR), @entity245 ( @entity245 ), and/or @entity154 ( @entity154 ), and individuals with multiple miscarriages (MM) who were karyotypically normal by standard G-banding techniques. METHODS: A total of 425 @entity1 were analyzed, of whom 372 had idiopathic MR/ @entity245 / @entity154 and 53 were involved in MM. An effort was made to select individuals for this study who were either normal karyotypically or who had @entity2008 that were inconclusive by banded chromosome analysis, although this was not always possible. RESULTS: Anomalies involving the subtelomere regions were detected at a frequency of 6.8% in the MR/ @entity245 / @entity154 group. The cryptic or subtle anomalies are estimated to be about 3.4%. It was necessary to use @entity24328 , chromosome, and locus specific FISH probes to clarify some of the abnormalities. No abnormalities were detected in the MM group. Deletion variants were present for 2qter, 7pter, and Xpter/Ypter subtelomeric regions ranging from <1 to 9.6%. CONCLUSIONS: The subtelomeric FISH probes are instrumental in the detection of @entity154 in a significant proportion, although no more than 50% are subtle, of @entity1 with idiopathic MR/ @entity245 / @entity154 . In some cases, however, it was necessary to use other FISH probes to clarify the nature of these abnormalities. No @entity854 were detected in our group of 53 MM @entity1 , suggesting a relatively low frequency of occurrence in this @entity1 population.

title: Utility of subtelomeric fluorescent DNA probes for detection of @entity2008 in 425 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['nonspecific dysmorphic features', 'subtelomeric anomalies', 'NDF']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['idiopathic mental retardation']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['DD', 'developmental delay']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['subtelomeric abnormalities']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['subtle chromosomal anomalies']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Several studies have shown that @entity5 cells may develop resistance to radiotherapy, proliferating under @entity519 conditions. Following surgery, @entity1 may develop low hemoglobin levels, which may cause low @entity26 conditions. This retrospective analysis was undertaken to determine the impact of low hemoglobin levels in @entity1 with @entity135 treated with combined-modality therapy (surgery and postoperative radiochemotherapy). We studied 120 @entity1 with mostly advanced @entity135 (88% stage III/IV) who had undergone macroscopically complete resections of their primary @entity5 and lymph node @entity3 . At 20-277 days after surgery (median: 51.3 days), these @entity1 received postoperative chemoradiotherapy (56.7 Gy of radiation over 28-49 days and @entity900 6 mg/m(2) body surface area on radiation treatment days with a cumulative dose of 96 mg/m(2)). Normal hemoglobin levels were considered to be 12 g/dl for females and 13 g/dl for males. Decreased hemoglobin levels before or after surgery and before or after chemoradiotherapy were correlated with the prognosis. Preoperatively, 99 of 114 @entity1 (87%) had normal levels of hemoglobin compared with only 20 of 107 @entity1 (19%) postoperatively. At the onset of radiochemotherapy, the hemoglobin levels of 82 of 116 @entity1 (71%) were within the normal range. After radiochemotherapy, however, 62 of 114 @entity1 (54%) had normal hemoglobin levels. Univariate analysis (Kaplan-Meier method and log-rank test) showed that @entity1 with decreased pre- or postoperative hemoglobin levels had significantly worse locoregional control ( P=0.032 and P=0.0001, respectively) and lower overall survival ( P=0.0013 and P=0.0002, respectively) than @entity1 with normal hemoglobin levels. The 3-year locoregional control rates in @entity1 with preoperative hemoglobin levels that were normal, were reduced by 1-2 g/dl or were reduced by more than 3 g/dl, respectively, were 78%, 55% and 50%. Correlated with normal and diminished postoperative hemoglobin levels, the 3-year locoregional control rates were 90%, 84% and 50%, respectively. There was no correlation between prognosis and hemoglobin level at the onset or after radiochemotherapy. On multivariate analysis, only the postoperative hemoglobin level remained a prognostic factor for locoregional control ( P=0.0241) and overall survival ( P=0.0080). We conclude that low postoperative hemoglobin levels resulting from @entity190 may influence the efficacy of postoperative radiochemotherapy in @entity1 with @entity135 . Early intervention to raise the postoperative hemoglobin level may result in @entity5 control and overall survival after combined-modality therapy.

title: Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'head and neck tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'better tumor', 'tumors']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity135 :: (MESH:D006258,Disease) :: ['head and neck tumors']


abstract: BACKGROUND: Chronic post-traumatic @entity10 (PTH) is one of the most common symptoms of mild @entity131 (mTBI) but its underlying mechanisms remain unknown. Inflammatory degranulation of dural mast cells (MCs) is thought to promote @entity10 , and may play a role in PTH. Whether mTBI is associated with persistent degranulation of dural MCs is yet to be determined. METHODS: Histochemistry was used to evaluate time course changes in dural MC density and degranulation level in concussive @entity542 and blast @entity19 models of mTBI. The effects of @entity9251 and the MC stabilizer cromolyn @entity1372 on concussion-evoked dural MC degranulation were also investigated. RESULTS: Concussive @entity542 evoked persistent MC degranulation for at least 30 days. Blast @entity130 gave rise to a delayed MC degranulation response commencing at seven days that also persisted for at least 30 days. Neither @entity9251 nor cromolyn treatment reduced concussion-evoked persistent MC degranulation. CONCLUSIONS: mTBI evoked by closed @entity542 or blast exposure is associated with persistent dural MC degranulation. Such a response in mTBI @entity1 may contribute to PTH. Amelioration of PTH by @entity9251 may not involve @entity450 . If persistent dural MC degranulation contributes to PTH, then cromolyn treatment may not be effective.

title: Responses of dural mast cells in concussive and blast models of mild XXXX in @entity19 : Potential implications for post-traumatic @entity10 .

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head trauma', 'head injury']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['inhibition of dural MC degranulation']

entities_list: @entity9251 :: ('MESH:D018170', 'Chemical') :: ['sumatriptan']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity131 :: (MESH:D001930,Disease) :: ['traumatic brain injury']


abstract: We reviewed 20 @entity1 receiving @entity5305 for @entity739 . @entity1 were not enrolled in a formal study. All families obtained the medication abroad. Age at initiation of @entity5305 ranged from 1 to 48 months; nine @entity1 had received prior treatment with various antiepileptic medications. @entity1 were begun on the lowest practical dose of 125-250 mg/day, with gradual daily increments to a target of 100 mg/kg/day, but maintained at the lowest effective dosage. Video electroencephalogram was obtained to document resolution of @entity2473 and @entity739 . Of 20 @entity1 , 12 responded with cessation of @entity2473 and resolution of @entity739 , at doses of 25-135 mg/kg/day (median = 58 mg/kg/day). Partial responses were observed in six @entity1 , whereas two had no response at 111 and 125 mg/kg/day. Additional new @entity410 types developed in three @entity1 after initial response to @entity5305 . Increasing the @entity5305 did not have any clinical benefit. @entity5305 is an effective, well-tolerated treatment for @entity739 . The response is dose-independent, suggesting that starting at a low dose and gradually increasing, rather than beginning with an arbitrary 100 mg/kg/day dose is advantageous.

title: XXXX for @entity739 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'infants']

entities_list: @entity5305 :: ('MESH:D020888', 'Chemical') :: ['vigabatrin', 'Vigabatrin']

entities_list: @entity739 :: ('MESH:D013036', 'Disease') :: ['hypsarrhythmia', 'infantile spasms']

answer: @entity5305 :: (MESH:D020888,Chemical) :: ['Vigabatrin']


abstract: Eph receptors and their cognate ligands ephrins are important players in axon guidance and neural patterning during development of the nervous system. Much of our knowledge about the signal transduction pathways triggered by Eph receptors has been related to the modulation of actin cytoskeleton, which is fundamental in mediating the cellular responses in growth cone navigation, cell adhesion, and cell migration. In contrast, little was known about whether long term activation of Eph receptor would regulate gene expression. Here we report a novel signaling pathway of @entity13388 , which involves activation of the @entity669 kinase @entity16404 and the transcriptional activator @entity10433 . Transfection of COS7 cells with @entity13388 , but not the kinase-dead mutant, induced @entity669 phosphorylation of @entity16404 , @entity16279 , and @entity10433 . Treatment of cultured C2C12 myotubes with @entity55890 also induced @entity669 phosphorylation of @entity10433 , which was abolished by the @entity16404 inhibitor @entity22943 . Moreover, @entity16404 was co-immunoprecipitated with @entity13388 in muscle, and both proteins were concentrated at the neuromuscular junction (NMJ) of adult muscle. By using microarray analysis, we have identified @entity4360 , the critical enzyme that hydrolyzed the neurotransmitter @entity934 at the NMJ, as a downstream target gene of the Jak/Stat pathway in muscle. More importantly, @entity55890 increased the expression of @entity4360 protein in C2C12 myotubes, which was abolished by @entity22943 . In contrast, @entity55890 reduced the expression of fibronectin mRNA in C2C12 myotubes independently of @entity16404 . Finally, the expression level of @entity4360 in limb muscle of @entity13388 null @entity19 was significantly reduced compared with the wild-type control. Taken together, these results have identified Jak/Stat proteins as the novel downstream targets of @entity13388 signaling. In addition, the present study provides the first demonstration of a potential function of Eph receptors and Jak/Stat proteins at the NMJ.

title: Identification of the Jak/Stat proteins as novel downstream targets of XXXX signaling in muscle: implications in the regulation of @entity4360 expression.

entities_list: @entity4360 :: ('11423(Tax:10090)', 'Gene') :: ['acetylcholinesterase']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity13388 :: (13838(Tax:10090),Gene) :: ['EphA4']


abstract: UNASSIGNED: Purpose To investigate the possibility of using @entity32735 ( @entity32736 )-enhanced molecular magnetic resonance (MR) imaging and optical imaging to identify the true margins of @entity11 . Materials and Methods The animal protocol was approved by the institutional animal care and use committee. Thirty-six @entity35 with @entity11 were randomized into six groups of six @entity35 . Five groups were euthanized 15, 30, 60, 120, and 240 minutes after intravenous administration of 6 mg/kg of @entity32736 , while one group received only saline solution as a control group. After craniotomy, optical imaging and T1-weighted MR imaging were performed to identify the @entity5 margins. One-way analysis of variance was used to compare optical photon intensity and MR imaging signal-to-noise ratios. Histologic analysis was performed to confirm the intracellular uptake of @entity32736 by @entity5 cells and to correlate the @entity5 margins delineated on both optical and MR images. Results Both optical imaging and T1-weighted MR imaging showed @entity5 margins. The highest optical photon intensity (2.6 * 10(8) photons per second per mm(2)    2.3 * 10(7); analysis of variance, P < .001) and MR signal-to-noise ratio (77.61    2.52; analysis of variance, P = .006) were reached at 15-30 minutes after administration of @entity32736 , with continued @entity5 visibility at 2-4 hours. Examination with confocal microscopy allowed confirmation that the fluorescence of optical images and MR imaging T1 enhancement exclusively originated from @entity32736 that accumulated in the cytoplasm of @entity5 cells. Conclusion @entity32736 -enhanced optical and MR imaging can allow determination of @entity5 margins at the optimal time of 15-120 minutes after administration of @entity32736 . Clinical application of these results may @entity11 in a hybrid surgical setting in which intraoperative optical and MR imaging are available. (  ) RSNA, 2015.

title: @entity11 : XXXX -enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'glioma tumor']

entities_list: @entity32735 :: ('MESH:C437683', 'Chemical') :: ['motexafin gadolinium']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas', 'allow complete removal of gliomas']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

answer: @entity32735 :: (MESH:C437683,Chemical) :: ['Motexafin Gadolinium']


abstract: UNASSIGNED: The aim of the study was to determine the effects of two different fat sources ( @entity1460 oil (SO) and beef tallow (BT)) in dry extruded @entity235 diets on the intake of food and metabolizable energy (ME), on faecal characteristics and apparent total tract digestibility (ATTD) of nutrients and energy. Ten adult @entity235 of different breeds were used in a Latin square design. Five experimental diets were designed from a basal diet. A Control diet was coated with 1% SO and four other diets were obtained by coating the basal diet with 6.5% and 13% of SO or BT. The Control, 6.5% and 13% coated diets contained approximately 8.5%, 15% and 20% fat, respectively. The @entity235 had similar @entity62 ( @entity62 ) intakes and, consequently, higher ME intakes with an increased fat content for both sources (p  <  0.05). Fat digestibility was highest for Diet SO13% (p  <  0.05). The ATTD of @entity62 and organic matter was highest (p  <  0.05) for Diets SO13% and BT13%. Fat coating improved the faecal score, especially for Diet BT13%. The dietary ratios of protein:fat: @entity1735 [% of ME] were close to AAFCO's estimates. For SO a higher ATTD (99.1%) and ME content (38.88  MJ/kg) was estimated than for BT (ATTD 92.9% and 36.37 MJ ME/kg). Both SO and BT can comprise up to 13% of the diet. However, SO was more susceptible to leaking from the kibbles with the coating method applied.

title: @entity1460 oil and beef tallow in dry extruded diets for adult XXXX .

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['DM', 'dry matter']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: The relation between the morphologic configuration of QRS complexes during wide QRS @entity591 induced during electrophysiologic studies and sinus rhythm was examined in 18 @entity1 who had preexisting left or @entity714 . Representative QRS complexes during sinus rhythm and during @entity591 were isolated from each @entity1 and juxtaposed for comparison. The QRS complexes that constituted each pair were judged by 4 observers as being identical, different or, if the decision was equivocal, similar. Nine @entity1 had @entity4710 ( @entity4710 ). In 8 of the 9 @entity1 , all 4 observers found the QRS complexes during sinus rhythm and @entity4710 identical in morphologic configuration. In the other @entity1 , 2 observers found the QRS complexes identical and 2 found them similar. In 12 @entity1 @entity1165 ( @entity1165 ) was induced. In 11 of these 12, all 4 observers found the QRS complexes during @entity1165 different from their respective sinus beats. In the other @entity1 , 3 observers found the QRS complexes different, whereas the fourth found them similar. During @entity4710 , the QRS duration was unchanged from the corresponding value during sinus rhythm, whereas in @entity1 with @entity1165 , QRS width increased by a mean of 56 +/- 20 ms (p less than 0.001). The results of our study suggest that the electrocardiographic differentiation of wide QRS @entity591 in @entity1 with preexisting @entity5036 can be accomplished easily and accurately by comparing the QRS complexes during @entity591 with those during sinus rhythm: If the complexes are identical, the @entity591 is supraventricular, but if they are different, the @entity943 is ventricular in origin.

title: Value of preexisting XXXX in the electrocardiographic differentiation of supraventricular from ventricular origin of wide QRS @entity591 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['VT', 'ventricular tachycardia']

entities_list: @entity714 :: ('MESH:D002037', 'Disease') :: ['right bundle branch block']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity5036 :: ('OMIM:113900', 'Disease') :: ['bundle branch block']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachycardia', 'SVT']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity5036 :: (OMIM:113900,Disease) :: ['bundle branch block']


abstract: @entity5125 is a food-borne pathogen of significant threat to public health. @entity101 ( @entity101 ) treatment can be used to control @entity5125 in food. The CtsR (class three stress gene repressor) protein negatively regulates the expression of class III heat shock genes. A spontaneous pressure-tolerant ctsR mutant 2-1 that was able to survive under @entity101 treatment has been identified previously. So far, there is only limited information about the mechanisms of survival and adaptation of this mutant to high pressure. Microarray technology was used to monitor the gene expression profiles of the ctsR mutant 2-1 under @entity101 treatment. Compared to pressure-treated @entity5125 Scott A wild type, 17 genes were up-regulated (>2-fold increase) in the ctsR mutant 2-1, whereas 58 genes were down-regulated (<-2-fold decrease). The entire clpC operon was up-regulated in the ctsR mutant 2-1, indicating that the mutant CtsR protein was not a functional repressor. The increased levels of expression of stress-related genes in ctsR mutant 2-1 may contribute to its survival under high pressure. The reduced expression levels of the genes related to virulence, flagella synthesis, and cell division in the ctsR mutant 2-1 correlate with its characteristics (elongated cells, reduced virulence, and @entity2048 ). The gene expression changes determined by microarray assays were confirmed by real-time reverse transcriptase PCR analyses. This study enhances our understanding of how @entity5125 survives under @entity101 and may contribute to the design of effective and economically feasible @entity101 treatment in food processing.

title: Gene expression profiling of a pressure-tolerant XXXX Scott A ctsR deletion mutant.

entities_list: @entity5125 :: ('1639', 'Species') :: ['Listeria monocytogenes', 'L. monocytogenes']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['HHP', 'High hydrostatic pressure']

entities_list: @entity2048 :: ('MESH:D004832', 'Disease') :: ['absence of flagella']

answer: @entity5125 :: (1639,Species) :: ['Listeria monocytogenes']


abstract: Purpose. To evaluate the relationship between the expression of orbital tissue mRNA for @entity403 , @entity4386 / @entity1361 / @entity7938 / @entity2937 , and @entity2936 / @entity2936 and the severity of @entity2743 ( @entity2743 ). Material and Methods. Orbital tissue was obtained from 26 @entity1 with @entity2743 , with mild (n = 6) or severe @entity2743 (n = 20), and 7 healthy controls. The expression of mRNA of @entity403 , @entity4386 / @entity1361 / @entity7938 / @entity2937 , @entity2936 / @entity11603 was measured by RT-PCR. TCR and CD3 were evaluated by immunohistochemistry. Results. Higher mRNA for @entity403 (relative expression: 1.4) and @entity2936 (1.27) and lower expression of @entity4386 (0.61) were found in the @entity2743 tissues versus controls. In severe @entity2743 as compared to mild @entity2743 higher mRNA expression for @entity403 (1.35) and @entity2936 (1.4) and lower expression for @entity4386 (0.78), @entity1361 (0.62), and @entity11603 (0.56) were found. A positive correlation was found between @entity403 mRNA and CD3 infiltration (R = 0.796, P = 0.0000001). Conclusions. The enhanced @entity403 mRNA expression in @entity2743 samples may suggest the dysfunction of @entity403 cells in the severe @entity2743 . The diminished mRNA expression of @entity4386 in severe @entity2743 may indicate inadequate T regulatory function. The enhanced mRNA expression of @entity2936 in severe @entity2743 and negative correlation to @entity1851 mRNA may suggest their role in the active and inactive @entity2743 .

title: Disturbances of Modulating Molecules ( @entity403 , XXXX / @entity1361 /B7, and @entity2936 / @entity11603 ) mRNA Expressions in the Orbital Tissue from @entity1 with Severe Graves' Ophthalmopathy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2743 :: ('MESH:D006111', 'Disease') :: ['GO', "Graves' orbitopathy"]

answer: @entity4386 :: (1493,Gene) :: ['CTLA-4']


abstract: PURPOSE: Neoadjuvant chemotherapy (NC) is yet to be established as the definitive treatment regimen for locally advanced @entity0 (LABC). The aim of this study was to determine the efficacy and @entity137 of NC with @entity1259 and @entity1311 . METHODS: Between March 2007 and January 2009, 50 @entity1 with LABC were enrolled in an open-label, phase II, multicenter study carried out at five distinct institutions. All @entity1 were scheduled to receive four cycles of 60 mg/m(2) @entity1259 and 175 mg/m(2) @entity1311 every 3 weeks, preoperatively, unless they developed profound side effects or disease progression. After curative surgery, two additional cycles of chemotherapy were administered to @entity1 who had shown a positive response to NC. RESULTS: In all, 196 cycles of chemotherapy were administered preoperatively; 47 of the 50 @entity1 (94%) underwent all four cycles of designated treatment. Complete disappearance of invasive foci of the @entity5 , and negative axillary lymph nodes were confirmed in eight @entity1 (16.0%), post operation. The cumulative 5-year disease-free survival rate was 70.0% for @entity1 with complete remission (CR) and partial remission (PR), and 33.3% for @entity1 with @entity66 ( @entity66 ) and @entity74 ( @entity74 ) (p=0.018). The cumulative 5-year overall survival was 90.0% for @entity1 who achieved CR and PR and 55.6% for @entity1 who had @entity66 and @entity74 (p=0.001). @entity1398 (42.0%) was the most common grade 3/4 @entity137 . However, none of the @entity137 resulted in cessation of the treatment. CONCLUSION: The encouraging pathologic response observed in the @entity1 treated with @entity1259 plus @entity1311 NC in this study suggests that @entity1259 could be a substitute for @entity632 , which is the most @entity1370 agent.

title: A Phase II Trial of Neoadjuvant Chemotherapy with Genexol   ( @entity1311 ) and @entity1259 for Locally Advanced XXXX .

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['Neutropenia']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxic']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']


abstract: To monitor the compliance of @entity1 taking @entity1955 as replacement therapy for @entity1375 , the authors measured serum @entity9808 ( @entity9808 ), free @entity1955 index (FT4I), and free @entity1954 index (FT3I) in @entity1 attending the endocrine clinic. During a 6-month period, there were 159 visits by 132 @entity1 with @entity1375 . Five of the 132 @entity1 had @entity9808 levels greater than 12 microU/ml (normal, 0.3-5.7 microU/ml), with FT3I greater than 85 (normal, 70-160) and FT4I greater than 7 (normal, 4.2-11). Four others had @entity9808 greater than 6 microU/ml with normal FT3I and normal FT4I. These nine @entity1 had normal thyroid tests documented on replacement therapy in the past. Five of the nine admitted to discontinuing their medicine for more than 1 week or taking it erratically. Two untreated @entity1375 @entity1 had daily thyroid function tests after they were started on full replacement doses of @entity1955 . Both achieved FT4I greater than 4.2 by day 8 and FT3I greater than or equal to 70 by day 18, but serum @entity9808 concentration did not fall consistently below 20 microU/ml until day 23 in one @entity1 and day 21 in the other and did not fall to the normal range by discharge at day 37 in one @entity1 or day 42 in the other. Thus, although treatment with @entity1955 will normalize serum T4 and T3 concentrations within 3 weeks, normalization of serum @entity9808 may take several more weeks. This prospective study in a large out- @entity1 clinic shows that 4% of @entity1 with treated @entity1375 may have elevation of serum @entity9808 to more than twice the upper limit of normal, while serum T4 and T3 are clearly normal.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Serum XXXX concentration as an aid to monitoring compliance with thyroid hormone therapy in @entity1375 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['treated hypothyroidism', 'primary hypothyroidism', 'hypothyroid']

entities_list: @entity9808 :: ('MESH:C536917', 'Disease') :: ['TSH', 'thyroid-stimulating hormone']

entities_list: @entity1955 :: ('MESH:D013974', 'Chemical') :: ['thyroxine', 'levothyroxine']

entities_list: @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine']

answer: @entity9808 :: (MESH:C536917,Disease) :: ['TSH']


abstract: To investigate the clinical efficacy of adoptive immunotherapy using dendritic cells (DC) and cytokine-induced killer (CIK) cells combined with chemotherapy in multiple @entity1582 . The immunomodulatory effect of the therapy was discussed by detecting the levels of peripheral blood T cell subsets and CD4(+)CD25(+) regulatory cells (Treg). Fifty MM @entity1 were randomly divided into two groups: 24 cases in the simple chemotherapy group and 26 cases in the combined therapy group (chemotherapy plus DC/CIK immunotherapy). The therapeutic efficacy and the proportions of peripheral blood T cell subsets and Treg cells were compared between the two groups. The cellular immunity indicators were also compared, including @entity1199 , @entity379 , @entity3646 , @entity688 , AgNORs ratio and @entity2533 . After 3 weeks of treatment, the life quality and clinical efficacy of the combined therapy group were superior to those of the simple chemotherapy group (P<0.05). CD3(+)CD8(+) ratio, CD4(+)CD25(+) ratio, CD4(+)CD25(+)/CD4(+) ratio, CD4(+)CD25(+)FoxP3(+)/CD4(+)CD25(+) ratio, @entity3646 , @entity688 and @entity2533 levels of the combined therapy group were obviously lower than those of the simple chemotherapy group (P<0.05). The CD3(+)CD4(+)/CD3(+)CD8(+) ratio, AgNOR ratio, @entity1199 and @entity379 level and positive rate of @entity3223 in the combined therapy group were significantly higher than those of the simple chemotherapy group (P<0.05). These results indicated better immunomodulatory effect of the combined therapy. DC/CIK immunotherapy combined with chemotherapy has a good clinical efficacy and prospect for MM, reversing the @entity1198 to Th2 shift and increasing the anti- @entity5 capacity of the immune system.

title: Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple XXXX and the clinical efficacy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1582 :: (MESH:D009101,Disease) :: ['myeloma']


abstract: The aim of the present work was to study the behavioral effects elicited in adult @entity468 by the selective D1 agonist, @entity2344 , and the D2 agonist, @entity3828 , comparing their effects with those evoked by @entity3826 . In 10 adult @entity468 , 0.5, 1.0, 4.0, and 8.0 mg/kg IP of @entity2344 were administered at random. A dose-response effect was observed related to alertness, indifference, and locomotion. The overall effect of @entity2344 was inhibitory. To the same 10 animals, @entity3828 in doses of 0.25, 0.5, and 1.0 mg/kg were injected IP. This drug had an excitatory and more complex effect than what was observed with the D1 agonist. Increases in locomotion, in alertness, indifference, fear, olfaction, @entity384 , @entity1833 , limb flicking, and head shaking were recorded. @entity3826 given to the same @entity468 , in a dose equimolar to 1.0 mg/kg of @entity3828 , elicited behaviors that resembled those elicited by the latter drug, but of a lesser intensity and duration. The interval between the different treatments was approximately 2 months. These results show clearly that the D2 receptor is the main dopaminergic receptor involved in the mechanism of production of most of the behavioral effects produced by some of the dopaminergic agonist drugs like @entity3826 .

title: Behavioral effects evoked by @entity2344 and @entity3828 in adult XXXX .

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['pupillary dilation']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucination']

entities_list: @entity3826 :: ('MESH:D001058', 'Chemical') :: ['Apomorphine', 'apomorphine']

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: The @entity3978 composition and antioxidant properties of three Lysimachia species (L. nummularia L., L. vulgaris L. and @entity71793 L.) and their column chromatographic fractions were investigated. The antioxidant activity of herb extracts and 54 different column chromatographic fractions was evaluated using in vitro DPPH and @entity16376 decolorization tests. The total @entity3978 content was determined by spectrophotometric methods. The phenolic compounds of extracts of different Lysimachia species and their bioactive fractions were characterized by online chromatographic methods. For identification of the compounds, UV spectral data, accurate molecular mass and formula, as well as @entity15 and fragmentation patterns given by LC-DAD-ESI/ @entity15 / @entity15 and LC-ESI- TOF analyses were used. Quantification of the compounds was performed by LC-DAD using an external standard method. In the extracts, @entity14627 derivatives, @entity13259 , free flavonoid aglycones, and 11 various flavonoid glycosides were identified. @entity3096 composition of Lysimachia extracts showed significant differences. @entity71793 extracts had the strongest DPPH and @entity16376 + radical scavenger activity (IC50=43.3  g/mL and 21.3  g/mL), due to their high @entity41461 and @entity3092 - @entity71794 content. Correlation between @entity3978 content and radical scavenging activity of each column chromatographic fractions is also included.

title: XXXX composition and antioxidant capacity of three Lysimachia species.

entities_list: @entity3978 :: ('CHEBI:26195', 'Chemical') :: ['polyphenol']

entities_list: @entity3096 :: ('CHEBI:47916', 'Chemical') :: ['Flavonoid']

entities_list: @entity14627 :: ('MESH:C040048', 'Chemical') :: ['caffeic acid']

entities_list: @entity71794 :: ('CHEBI:35313', 'Chemical') :: ['hexoside']

entities_list: @entity41461 :: ('MESH:C008577', 'Chemical') :: ['myricitrin']

entities_list: @entity3092 :: ('MESH:D011794', 'Chemical') :: ['quercetin']

entities_list: @entity13259 :: ('MESH:D002726', 'Chemical') :: ['chlorogenic acid']

answer: @entity3978 :: (CHEBI:26195,Chemical) :: ['Polyphenol']


abstract: BACKGROUND: @entity7195 is recognized as a cause of early @entity570 . The purpose of this study was to prospectively determine the early clinical presentation of symptomatic @entity7195 in skeletally mature @entity1 . METHODS: Fifty-seven consecutive skeletally mature @entity1 with a total of sixty-five symptomatic hips were diagnosed with symptomatic @entity7195 on the basis of the history, physical examination, and radiographs. These fifty-seven @entity1 were enrolled in this study and were followed prospectively for a minimum of twenty-four months postoperatively. RESULTS: The study group included forty-one female @entity1 (72%) and sixteen male @entity1 (28%) with a mean age of twenty-four years. All were treated with a periacetabular osteotomy and were followed for a minimum of twenty-four months. The initial presentation was insidious in 97% of the hips, and the majority (77%) of the hips were associated with moderate-to-severe @entity158 on a daily basis. @entity158 was most commonly localized to the groin (72%) and/or the lateral aspect of the hip (66%). Activity-related @entity158 was common (88%), and activity restriction frequently diminished @entity158 (in 75% of the cases). On examination, thirty-one hips (48%) were associated with a limp; twenty-five (38%), with a positive Trendelenburg sign; and sixty-three (97%), with a positive impingement sign. The mean time from the onset of symptoms to the diagnosis of @entity572 was 61.5 months. The mean number of health-care providers seen prior to the definitive diagnosis was 3.3. The mean Harris hip score improved from 66.4 points preoperatively to 91.7 points at a mean of 29.2 months after the periacetabular osteotomy. CONCLUSIONS: The diagnosis of symptomatic @entity7195 is commonly delayed, and procedures other than a pelvic reconstructive osteotomy are frequently recommended. The diagnosis of @entity572 should be suspected and investigated when a skeletally mature, young, active @entity1 has a predominant complaint of insidious activity-related groin @entity158 and/or lateral @entity158 . LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions to Authors for a complete description of levels of evidence.

title: Clinical presentation of symptomatic XXXX in skeletally mature @entity1 .

entities_list: @entity7195 :: ('OMIM:142700', 'Disease') :: ['acetabular dysplasia', 'Acetabular dysplasia']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['developmental dysplasia of the hip', 'hip dysplasia']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'hip pain', 'pain']

entities_list: @entity570 :: ('MESH:D015207', 'Disease') :: ['degenerative hip osteoarthritis']

answer: @entity7195 :: (OMIM:142700,Disease) :: ['acetabular dysplasia']


abstract: The presence of @entity172 -independent @entity1420 receptors ( @entity7273 ) was demonstrated in a subline of a @entity1 @entity1204 cell line, Ishikawa cells, although the original Ishikawa cells contained @entity172 -inducible @entity7273 . Scatchard plot analysis of cytoplasmic binding data in our subline (IK-90) revealed a high affinity binding site for @entity18074 (Kd, 1.0 nM) with maximum binding sites of 158 fmol/mg protein. Competition experiments showed a binding specificity similar to that of typical @entity7273 . By low-salt @entity969 gradient centrifugation, radioactive 8S and 4S peaks were found. The addition of 1 microM @entity1420 in culture medium resulted in a rapid nuclear translocation of cytoplasmic @entity7273 . In contrast to the original cells, @entity172 receptors could not be detected in IK-90 cells, and an addition of @entity53 (10 nM) to culture medium failed to increase @entity7273 . Accumulation of glycogen in cytoplasm of IK-90 cells in response to @entity18074 (0.1-1 microM) was observed by periodic acid-Schiff staining. The addition of @entity18074 to culture medium (0.1-1 microM) also caused a marked decrease in the growth of IK-90 cells, whereas the other @entity230 including @entity53 , @entity440 , @entity251 , and @entity701 had no significant effects. These results demonstrate for the first time the presence of a progestin-responsive @entity1 @entity1204 cell line that contains @entity172 -independent functional @entity7273 . IK-90 cells appear to be an ideal model for studying the mechanism of the antiproliferative effect of progestin on @entity1204 cells.

title: Growth inhibition by progestins in a @entity1 @entity1204 cell line with @entity172 -independent XXXX receptors.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['17 beta-estradiol']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity1420 :: (MESH:D011374,Chemical) :: ['progesterone']


abstract: UNASSIGNED: MicroRNAs (miRNAs/miRs) are a class of short, single  -stranded nucleic acids, which have been investigated as potential molecular markers for various types of @entity5 . The gold  -standard and most sensitive method for comparing miRNA levels in @entity5 tissues is reverse transcription  -quantitative polymerase chain reaction (RT  -qPCR). This technique uses stably expressed genes for normalisation. The aim of the present study was to improve this model of analysis in the context of RT  -qPCR results. A total of six known miRNAs (let  -7a, @entity12425 , @entity13825 , @entity6557 , miR  -125b and @entity21275 ), @entity60709 RNA and five mRNAs [erb  -b2 receptor @entity4149 kinase  2 ( @entity1722 ), @entity56256 synthase and polymerase (RNA)  II (DNA directed) polypeptide A] were analysed pair  -wise, in order to determine which biomarker pairs best correlated with the histological groups of 27  @entity0 samples. The lowest P  -values and the highest area under the curve values in the receiver operating characteristic analysis were used to select the optimum ratios for discrimination among groups. Among the 21 pairs, @entity12425 / @entity13825 and @entity6557 / @entity60709 best discriminated three groups of samples with different @entity5 grades (G  classification). miR  -125b/ @entity21275 best discriminated two groups of samples with different @entity5 sizes (pT), let  -7a/ @entity60709 best discriminated two groups of samples with different lymph node status (pN), and let  -7a/miR  -125b best discriminated groups of samples with negative and positive @entity2931 and @entity1420 receptor status. No pair of miRNAs was found to discriminate well between groups with either a negative or positive @entity1 @entity1722 ( @entity1722 ) status. However, one miRNA/mRNA pair, @entity6557 / @entity1722 , discriminated @entity1722  -negative from @entity1722  -positive groups. The @entity0 samples investigated in the present study were grouped by immunohistological methods into three molecular classes: Luminal, @entity1722 positive and basal (L, H and B, respectively). In order to discern L from H and L from B, two miRNA pairs were selected: @entity6557 /miR  -125b and @entity6557 / @entity21275 . In conclusion, the pair  -wise method of RT  -qPCR data analysis may be a reasonable alternative to the standard method of using stably expressed reference genes, such as @entity60709 RNA, for normalisation. This method may increase the classification power of miRNA biomarkers in @entity0 diagnostics.

title: Relative levels of let  -7a, XXXX , @entity13825 , @entity6557 , miR  -125b and @entity21275 as potential molecular markers to evaluate grade, receptor status and molecular type in @entity0 .

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumour']

entities_list: @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogen']

entities_list: @entity56256 :: ('MESH:C024393', 'Chemical') :: ['hydroxymethylbilane']

entities_list: @entity1722 :: ('2064', 'Gene') :: ['ERBB2', 'epidermal growth factor receptor  2', 'HER2']

answer: @entity12425 :: (406952,Gene) :: ['miR  -17']


abstract: Treatment plan for neonates with @entity1375 (persistent hyperthyrotropinemia with normothyroxinemia) has not been established. In this study, changes in thyroid function after discontinuation of low-dose @entity1955 ( @entity2016 ) supplement in @entity1 with the condition were evaluated. Fourteen @entity1 with hyperthyrotropinemia at neonatal screening had repeated hyperthyrotropinemia (> 8 mU/L) with normothyroxinemia. TSH response was exaggerated at TRH testing. The subjects were treated with low-dose @entity2016 (3 to 9 microg/kg/day) for 2.2 to 6 years, and euthyroid status was maintained. After discontinuation of therapy, mild hyperthyrotropinemia persisted up to 24 months, while serum FT4 remained within the lower half of the normal range. TSH response to @entity1218 stimulation, which tended to be exaggerated 1 month after discontinuation, became lower 6 to 12 months later. RAIU and thyroid scintigraphy were normal in all subjects. No @entity1 developed hypothyroxinemia, although mild elevation of TSH lasted rather long after discontinuation of low-dose @entity2016 therapy. Administration of @entity2016 was not resumed provided the subjects were followed at regular interval. Further long-term investigation is needed to define whether re-administration is necessary or not.

title: Persistence of mild hyperthyrotropinemia after discontinuation of three-year course of low-dose XXXX therapy in @entity1 with @entity1375 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'infants']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['borderline hypothyroidism']

entities_list: @entity1955 :: ('MESH:D013974', 'Chemical') :: ['L-thyroxine']

answer: @entity1955 :: (MESH:D013974,Chemical) :: ['L-thyroxine']


abstract: PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity1072 ( @entity1072 ). Based on excellent results with the chemotherapy-only regimen @entity3118 , @entity786 , and @entity2664 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity1 AND METHODS: Seventy-two untreated @entity1072 @entity1 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity3118 25 mg/m(2) IV on days 1 to 3, @entity786 200 mg/m(2) on days 1 to 3, and @entity2664 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity1 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity41 ( @entity41 ) -negative complete response (CR), @entity41 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity1398 developed in 13% of @entity1 . Major and minor @entity281 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity2262 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity1072 , with an 82% CR rate and a high proportion of @entity41 -negative CRs (46%). Treatment @entity137 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity2262 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

title: Rituximab, XXXX , @entity786 , and @entity2664 : a new, highly active chemoimmunotherapy regimen for @entity1072 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease']

entities_list: @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia']

entities_list: @entity2262 :: ('567', 'Gene') :: ['beta2-microglobulin']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

answer: @entity3118 :: (MESH:C024352,Chemical) :: ['fludarabine']


abstract: Eighty-four @entity742 weaned at birth were randomised to three groups, each of 28 animals. The amount of @entity1388 contained in the feed was carefully assessed. Two groups were administered with @entity3163 . The dose was calculated so as to administer a quantity of @entity1388 close to the quantity that @entity742 would ingest in consuming alfalfa containing from 125 to 250 ppm @entity1388 . The daily amount of @entity1388 administered to the 1st group rose progressively between week 3 and week 8 from 0.45 to 2 mg/kg/day, then remained fixed until the animals were slaughtered. Group 2 received double amounts: from 0.90 mg/kg/day to 4 mg/kg/day between week 3 and week 8, at which level the amount was fixed. The treatment had no effect on the growth of the @entity742 : at week 17 their average weight was about 29 kg. Plasma levels of ionic @entity2862 rose steadily up to week 9, at which they remained fixed at about 0.40 mg/l in group 1 and 0.75 mg/l in group 2, whereas they ranged between 0.10 and 0.15 mg/l in the controls. Ionic @entity2862 averaged 28% of the total @entity1388 in the controls, 42% in group 1 and 47% in group 2. @entity1388 levels in the bones were very high (up to 2760 ppm in the mandibles in group 2). Reversely, @entity1388 levels in the muscles were very low: 1.00 ppm in group 2. The biochemical paremeters @entity460 , @entity3151 , @entity1760 , transaminases, phosphatases and @entity5428 transferases greatly varied in relation to the age of the animal but were not affected by @entity1388 intake.

title: [Experimental study of fluorosis in XXXX ].

entities_list: @entity5428 :: ('CHEBI:24190', 'Chemical') :: ['gamma glutamyl']

entities_list: @entity3163 :: ('MESH:D012969', 'Chemical') :: ['sodium fluoride']

entities_list: @entity2862 :: ('MESH:D005461', 'Chemical') :: ['fluorine']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']

entities_list: @entity1388 :: ('MESH:D005459', 'Chemical') :: ['fluoride', 'Fluoride']

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']

answer: @entity742 :: (9940,Species) :: ['lambs']


abstract: OBJECTIVE: To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal @entity2713 with observation for eyes with @entity1018 associated with @entity1103 secondary to perfused central @entity2994 (CRVO). METHODS: Multicenter, randomized, clinical trial of 271 @entity1 . MAIN OUTCOME MEASURE: Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS: Seven percent, 27%, and 26% of @entity1 achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of @entity2790 and @entity231 were similar for the observation and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS: Intravitreal @entity2713 is superior to observation for treating @entity1018 associated with @entity1103 secondary to CRVO in @entity1 who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal @entity2713 in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for @entity1 with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.

title: A randomized trial comparing the efficacy and safety of intravitreal @entity2713 with observation to treat @entity1018 associated with @entity1103 secondary to central @entity2994 : the Standard Care vs Corticosteroid for XXXX (SCORE) study report 5.

entities_list: @entity1018 :: ('MESH:D054062', 'Disease') :: ['vision loss']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema']

entities_list: @entity2790 :: ('MESH:D009798', 'Disease') :: ['elevated intraocular pressure']

entities_list: @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']

answer: @entity2994 :: (MESH:D012170,Disease) :: ['Retinal Vein Occlusion']


abstract: The present study was performed on conscious, chronically instrumented @entity235 , which underwent selective blockade of sympathetic adrenergic and vagal outflows. Excitements were performed on these animals in normal states (N), after chronic treatment with @entity2997 , for sympathetic blockade (SB), after cold vagal blockade (VB), and after combined sympathetic and vagal blockade (SB + VB). Heart rate and arterial blood pressure were monitored in all the experiments, while a group of @entity235 was also tested with an electromagnetic flowmeter on the superior mesenteric artery. The role of the sympathetic and parasympathetic controls in the defence reaction was assumed from comparison of experiments performed in the presence or in the absence of each (or both) autonomic component(s). In the SB + VB condition, excitement was followed by @entity551 , without changes in heart rate. In VB experiments, a brief and transient @entity551 appeared, followed by gradually developed @entity101 , while heart rate progressively rose in about 5 s; there was no sudden increase in mesenteric vascular resistance, which contrasted with the very marked reaction in N experiments. Under vagal control alone (SB), the stimulus elicited prompt @entity591 and @entity101 , followed by a period of moderately reduced blood pressure. We conclude that, while the defence reaction leads to a @entity551 , in the absence of compensatory mechanisms, both branches of the autonomic nervous system play a protective role against @entity551 . In addition, the modulation of the vagal outflow, leading to sudden changes in the heart performance, seems to be responsible for the initiation of the overall haemodynamic adjustments following excitements. The possibility that withdrawal of the parasympathetic outflow to the heart may raise arterial blood pressure was verified in a special experiment in which artificial vagal stimulation in a conscious (vagal blocked) @entity235 , was turned off for brief periods, before and after @entity2997 . This led to changes in blood pressure and heart rate very similar to those seen at the onset of the defence reaction, both in N and SB conditions.

title: Role of the autonomic nervous system in the control of heart rate and blood pressure in the defence reaction in conscious XXXX .

entities_list: @entity2997 :: ('MESH:D006145', 'Chemical') :: ['guanethidine']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['sudden fall of arterial blood pressure', 'sudden hypotension', 'hypotension']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: OBJECTIVE: To study the expression of @entity4043 ( @entity4043 )and @entity1495 ( @entity1495 ) in supraglottic, @entity189 , different distance surgical margins and lymphatic @entity3 ; to study the relationship of two molecular markers. METHOD: Expression of elF4E and @entity1495 in @entity189 and different margins were detected by HE-stained, routine pathological section, immunohistochemical SP method and image analysis. RESULT: (1) Immunohistochemical staining for @entity1495 was performed with a monoclonal anti- @entity1495 antibody. The positive expression rate was 68. 4 % . There was significant difference between lymph node @entity3 and no lymph node @entity3 , but there was no significant difference between @entity6402 or @entity6493 ( P >0. 05). There was no significant difference between @entity1495 and @entity189 position,pathology grade ( P> 0. 05). Positive expression rate of @entity1495 was @entity5 , 5 mm, 10 mm different distant margin of supraglottic and @entity189 as tissue progressed adjacent to @entity189 . (2) Staining positive rate of elF4E in supraglottic and @entity189 was 89%. There was significant association between @entity4043 expression intensity and clinical stage, lymphatic @entity3 . The positive expression rate of @entity4043 was increased in sequence from 10 mm, 5 mm distant mucosa tissue to @entity189 nest in supraglottic and @entity189 . (3) Negative expression of @entity1495 and @entity4043 was seen in the normal lymph nodes. @entity1495 positive expression rate was 28% in @entity3 lymph nodes,elF4E was 42 %. (4) There was no significant correlation between elF4E and @entity1495 in margins according to spearman rank correlation test. CONCLUSION: @entity4043 and @entity1495 expression was significantly higher in supraglottic and @entity189 than distant margin and normal mucosa tissue. elF4E positive rate was higher than @entity1495 ,expression sensitivity and reliability of elF4E in margins was higher than @entity1495 . elF4E is a sensitive marker in growth, infiltration and @entity3 of supraglottic and @entity189 .

title: [Expression and clinical value of eukaryotic initiation factor 4E and matrix metalloproteinase-9 in supraglottic and @entity189 and XXXX lymph].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['decreased in tumour']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['hypopharyngeal carcinoma', 'carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1495 :: ('4318', 'Gene') :: ['MMP-9', 'matrix metalloproteinase-9']

entities_list: @entity4043 :: ('1977', 'Gene') :: ['eIF4E', 'eukaryotic initiation factor4E']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']